

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

11-18

RRID:CVCL_6659

Type: Cell Line

Proper Citation

RRID:CVCL_6659

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_6659

Proper Citation: RRID:CVCL_6659

Description: Cell line 11-18 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Sex unspecified

Disease: Lung adenocarcinoma

Defining Citation: [PMID:9023415](#), [PMID:9538136](#), [PMID:14581340](#), [PMID:15746151](#), [PMID:16105816](#), [PMID:19472407](#), [PMID:20557307](#), [PMID:22313637](#), [PMID:22815900](#), [PMID:38639832](#)

Comments: Population: Japanese and Micro.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: 11-18

Synonyms: II-18

Cross References: CLO:CLO_0050051, BioSample:SAMN03472059, cancercellines:CVCL_6659, Cell_Model_Passport:SIDM01637, CGH-DB:201-1, CGH-DB:9163-4, Cosmic:889084, Cosmic:946048, Cosmic:1066156, Cosmic:1239901, Cosmic:1336877, Cosmic:1656892, Cosmic:1731372, Cosmic:2125265, IARC_TP53:28444, RCB:RCB2093, TKG:TKG 0177, Wikidata:Q54897419

ID: CVCL_6659

Record Creation Time: 20220427T215030+0000

Ratings and Alerts

No rating or validation information has been found for 11-18.

No alerts have been found for 11-18.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Marrocco I, et al. (2023) L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab. Cell reports. Medicine, 4(8), 101142.

Martin MJ, et al. (2022) Pharmaceutical Reactivation of Attenuated Apoptotic Pathways Leads to Elimination of Osimertinib Drug-Tolerant Cells. Cancer research communications, 2(10), 1312.